Quanterix (QTRX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$153.4M

Revenue (quarter)

$32.9M

Revenue growth (year over year)

+34.44%

Gross profit (trailing twelve months)

$68.4M

Gross margin

44.56%

Net income (trailing twelve months)

−$123.1M

Net income (quarter)

−$48.9M

Net income growth (year over year)

−63.04%

Net margin

−80.25%

Return on equity

−46.48%

EPS (trailing twelve months)

−$2.62

Book value per share

$5.03

P/E (trailing twelve months)

—

Price to book

0.63

Debt to assets

25.78%

Payout ratio

—

Dividend yield

—

Company profile

Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.

• Is Quanterix (QTRX) profitable?

  No. Quanterix reported a net loss of $123.1M over the trailing twelve months.

• How much revenue does Quanterix (QTRX) make?

  Quanterix generated $153.4M in revenue over the trailing twelve months, up 34.44% year over year.

• How do I buy stock in Quanterix (QTRX)?

  QTRX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.